CLINICAL ACTIVITY AND PHARMACOKINETICS (PK) OF CABOZANTINIB (XL184) IN PATIENTS WITH PROGRESSIVE MEDULLARY THYROID CARCINOMA (MTC)

被引：0
|
作者：
Cohen, E. E. W. [1 ]
Elisei, R. [2 ]
Schlumberger, M. J. [3 ]
Mueller, S. P. [4 ]
Schoeffski, P. [5 ]
Brose, M. [6 ]
Shah, M. [7 ]
Miles, D. R. [8 ]
Nguyen, L. T. [8 ]
Sherman, S. [9 ]
机构：
[1] Univ Chicago, Med Ctr, Dept Med, Chicago, IL 60637 USA
[2] Univ Pisa, Dept Endocrinol, Pisa, Italy
[3] Inst Canc Res, Villejuif, France
[4] Univ Klinikum Essen, Klin & Poliklin Nukl Med, Essen, Germany
[5] Univ Hosp Leuven, Dept Gen Med Oncol, Louvain, Belgium
[6] Univ Penn Hlth Syst, Dept Med, Philadelphia, PA USA
[7] Ohio State Univ, Coll Med, Columbus, OH 43210 USA
[8] Exelixis Inc, Nonclin Dev, San Francisco, CA USA
[9] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disord, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：154 / 155
页数：2
相关论文
共 50 条
  • [1] XL184 (cabozantinib) for medullary thyroid carcinoma
    Durante, Cosimo
    Russo, Diego
    Verrienti, Antonella
    Filetti, Sebastiano
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (03) : 407 - 413
  • [2] Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer
    Viola, David
    Cappagli, Virginia
    Elisei, Rossella
    FUTURE ONCOLOGY, 2013, 9 (08) : 1083 - 1092
  • [3] Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
    Kurzrock, Razelle
    Sherman, Steven I.
    Ball, Douglas W.
    Forastiere, Arlene A.
    Cohen, Roger B.
    Mehra, Ranee
    Pfister, David G.
    Cohen, Ezra E. W.
    Janisch, Linda
    Nauling, Forlisa
    Hong, David S.
    Ng, Chaan S.
    Ye, Lei
    Gagel, Robert F.
    Frye, John
    Mueller, Thomas
    Ratain, Mark J.
    Salgia, Ravi
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (19) : 2660 - 2666
  • [4] Antitumor activity of cabozantinib (XL184) in a cohort of patients (pts) with differentiated thyroid cancer (DTC)
    Cabanillas, Maria E.
    Brose, Marcia S.
    Ramies, David A.
    Lee, Yihua
    Miles, Dale
    Sherman, Steven I.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] A Phase I Study of Cabozantinib (XL184) in Patients with Differentiated Thyroid Cancer
    Cabanillas, Maria E.
    Brose, Marcia S.
    Holland, Jaymes
    Ferguson, Kimberly C.
    Sherman, Steven I.
    THYROID, 2014, 24 (10) : 1508 - 1514
  • [6] Activity of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC).
    Choueiri, Toni K.
    Pal, Sumanta Kumar
    McDermott, David F.
    Ramies, David A.
    Morrissey, Stephanie
    Lee, Yihua
    Miles, Dale
    Holland, Jaymes S.
    Dutcher, Janice P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [7] In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer
    Bentzien, Frauke
    Zuzow, Marcus
    Heald, Nathan
    Gibson, Anna
    Shi, Yongchang
    Goon, Leanne
    Yu, Peiwen
    Engst, Stefan
    Zhang, Wentao
    Huang, Donghui
    Zhao, Lora
    Vysotskaia, Valentina
    Chu, Felix
    Bautista, Rajana
    Cancilla, Belinda
    Lamb, Peter
    Joly, Alison H.
    Yakes, F. Michael
    THYROID, 2013, 23 (12) : 1569 - 1577
  • [8] A phase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma
    Apolo, Andrea Borghese
    Parnes, Howard L.
    Madan, Ravi Amrit
    Gulley, James L.
    Wright, John Joseph
    Khadar, Kattie
    Trepel, Jane B.
    Schlom, Jeffrey
    Arlen, Philip M.
    Merino, Maria
    Steinberg, Seth M.
    Choyke, Peter L.
    Lindenberg, Maria Liza
    Kurdziel, Karen A.
    Folio, Les
    Figg, William Douglas
    Agarwal, Piyush K.
    Bottaro, Donald P.
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline
    Schoffski, Patrick
    Elisei, Rossella
    Mueller, Stefan
    Brose, Marcia S.
    Shah, Manisha H.
    Licitra, Lisa F.
    Jarzab, Barbara
    Medvedev, Viktor
    Kreissl, Michael
    Niederle, Bruno
    Cohen, Ezra E. W.
    Wirth, Lori J.
    Ali, Haythem Y.
    Hessel, Colin
    Yaron, Yifah
    Ball, Douglas Wilmot
    Nelkin, Barry
    Sherman, Steven I.
    Schlumberger, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC)
    Choueiri, Toni K.
    Pal, Sumanta Kumar
    McDermott, David F.
    Ramies, David A.
    Morrissey, Stephanie
    Lee, Yihua
    Miles, Dale
    Holland, Jaymes
    Dutcher, Janice P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345